News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,106 Results
Type
Article (8048)
Company Profile (140)
Press Release (475917)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166774)
Career Advice (310)
Deals (25743)
Drug Delivery (7)
Drug Development (52894)
Employer Resources (14)
FDA (9765)
Job Trends (8577)
News (238245)
Policy (17908)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (485)
Accelerated approval (23)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33156)
ALS (103)
Alzheimer's disease (972)
Antibody-drug conjugate (ADC) (262)
Approvals (10367)
Artificial intelligence (317)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6962)
BIO (36)
BIOSECURE Act (1)
Biosimilars (107)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (505)
Cancer (3616)
Cardiovascular disease (216)
Career advice (249)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (474)
Cervical cancer (34)
Clinical research (47831)
Collaboration (1230)
Commercialization (2)
Compensation (1436)
Complete response letters (34)
COVID-19 (755)
CRISPR (63)
C-suite (729)
Cystic fibrosis (84)
Data (5580)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (339)
Diagnostics (4173)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73471)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87566)
Executive appointments (695)
FDA (12355)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (901)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (290)
Government (946)
Grass and pollen (2)
Guidances (280)
Healthcare (9313)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (155)
Infectious disease (943)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (249)
Interviews (42)
IPO (12386)
IRA (2)
Job creations (1969)
Job search strategy (239)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (5)
Liver cancer (44)
Longevity (15)
Lung cancer (501)
Lymphoma (248)
Machine learning (27)
Management (3)
Manufacturing (524)
Marketing (7)
MASH (117)
Medical device (8649)
Medtech (8787)
Mergers & acquisitions (14377)
Metabolic disorders (699)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (218)
Neuropsychiatric disorders (38)
Neuroscience (1812)
NextGen: Class of 2026 (3153)
Non-profit (842)
Obesity (221)
Opinion (11)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (193)
Parkinson's disease (200)
Partnered (11)
Patents (464)
Patient recruitment (497)
Peanut (31)
People (41192)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15458)
Phase 2 (21362)
Phase 3 (14393)
Pipeline (6998)
Policy (18)
Postmarket research (1572)
Preclinical (6532)
Press Release (34)
Prostate cancer (188)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (567)
Real estate (3020)
Recruiting (6)
Regulatory (14774)
Reports (17)
Research institute (579)
Resumes & cover letters (46)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (151)
Series B (119)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2018)
Stomach cancer (3)
Supply chain (50)
Vaccines (317)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (40)
Last 7 days (525)
Last 30 days (1440)
Last 365 days (19066)
2026 (11661)
2025 (19251)
2024 (22988)
2023 (26538)
2022 (34594)
2021 (37184)
2020 (33481)
2019 (23284)
2018 (17472)
2017 (18771)
2016 (17919)
2015 (24271)
2014 (21686)
2013 (18136)
2012 (20226)
2011 (20446)
2010 (20332)
Location
Africa (228)
Alabama (72)
Alaska (2)
Arizona (299)
Arkansas (11)
Asia (17874)
Australia (2096)
California (11775)
Canada (3095)
China (512)
Colorado (475)
Connecticut (400)
Delaware (205)
Europe (24610)
Florida (1757)
Georgia (370)
Hawaii (3)
Idaho (46)
Illinois (691)
India (45)
Indiana (314)
Iowa (14)
Japan (395)
Kansas (99)
Kentucky (30)
Louisiana (26)
Maine (25)
Maryland (1180)
Massachusetts (7763)
Michigan (305)
Minnesota (555)
Mississippi (4)
Missouri (79)
Montana (20)
Nebraska (11)
Nevada (113)
New Hampshire (60)
New Jersey (2586)
New Mexico (12)
New York (2785)
North Carolina (1255)
North Dakota (4)
Northern California (5883)
Ohio (273)
Oklahoma (14)
Oregon (16)
Pennsylvania (2231)
Puerto Rico (20)
Rhode Island (30)
South America (407)
South Carolina (76)
South Dakota (1)
Southern California (4890)
Tennessee (116)
Texas (1901)
United States (38300)
Utah (356)
Vermont (1)
Virginia (151)
Washington D.C. (38)
Washington State (910)
West Virginia (1)
Wisconsin (73)
484,106 Results for "zogenix inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
UCB to acquire Zogenix
Regulated information – Inside information – UCB and Zogenix announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.
January 19, 2022
·
19 min read
Deals
UCB Completes Acquisition of Zogenix, Inc.
UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ: ZGNX) for US$ 26.00 per share plus a milestone-based contingent value right for a potential cash payment of US$ 2.00 per share.
March 7, 2022
·
15 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Deals
Zogenix Reports Granting of Inducement Awards
Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen (14) new employees.
September 16, 2021
·
1 min read
Biotech Bay
Zogenix Reports Granting of Inducement Awards - Dec 16, 2021
Zogenix announced that the compensation committee of the company’s board of directors granted inducement awards to nine new non-executive employees.
December 16, 2021
·
2 min read
Biotech Bay
Zogenix Reports Granting of Inducement Awards - Nov 17, 2021
Zogenix announced that the compensation committee of the company’s board of directors granted inducement awards to thirteen new non-executive employees.
November 17, 2021
·
1 min read
Biotech Bay
Zogenix to Participate in Two Upcoming Investor Conferences - Nov 11, 2021
Zogenix, a global biopharmaceutical company developing rare disease therapies, announced that members of its management team will participate in fireside chats at two upcoming investor conferences: the Stifel 2021 Virtual Healthcare Conference and Guggenheim Virtual 3rd Annual Neuro/Immunology Conference.
November 11, 2021
·
1 min read
Press Releases
FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
July 29, 2026
·
6 min read
Biotech Bay
Zogenix Reports Granting of Inducement Awards - Aug 16, 2021
Zogenix announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen new employees.
August 16, 2021
·
1 min read
Business
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
Zogenix, a global biopharmaceutical company developing and rare disease therapies, provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2021.
February 28, 2022
·
13 min read
1 of 48,411
Next
